Lai

5

WHAT IS CLAIMED IS:

- 1. A method for identifying the candidate proteins useful as anti- infectives, which comprises:
- i) calculating computationally the different sequence based attributes from all the protein sequences of the selected pathogenic organisms.
- ii) clustering computationally all the proteins of a genome based on these sequence-based attributes using Principle Component Analysis.
- iii) identifying computationally the outlier proteins sequences which are excluded from the main cluster.
- iv) matching the outlier protein sequences with the protein sequences in various databases.
- v) selecting the unique outlier protein sequences not homologous to any of the protein sequences searched above.
- vi) validating computationally the protein sequences as anti-infectives by comparing with the known protein sequences that are biochemically characterized in the pathogen. genome.
- 2. A method claimed in claim 1 wherein, the protein sequence data is taken from any organism, specifically but not limited to organisms such as B.burgdorfei, C.jejuni, C.pneumoniae, C.trachomatis, H.influenzae, H.pylori, L.major, M.genetalium, M.pneumoniae, M.tuberculosis, N.meningitis, P.aeruginosa, P.falciparum, R.prowazekii, T.pallidum, V.cholerae.

- 3. A method claimed in claim 1 wherein different sequence-based attributes used for identification of candidate anti-infective proteins are selected from the group co9mprising of fixed protein and variable protein attributes.
- 4. A method claimed in claim1wherein the fixed protein attributes are selected from the group comprising of percentage of charged amino acids, percentage hydrophobicity, distance of protein sequence from a fixed reference frame, measure of dipeptide complexity of protein, and measure of hydrophobic distance from a fixed reference frame.
- 5. A method as claimed in claim 3 wherein the variable attribute is the distance of the protein sequence from a variable reference frame.
- 6. A method as claimed in claim 1, wherein the cluster analysis is carried out by Principle Analysis Technique using correlation coefficient between the attributes.
- 7. A method as claimed in claim 1, wherein the steps I to iv and vi are performed computationally.
- 8. A method as claimed in claim 1, wherein the clustering of the proteins is based upon analysis of sequence attributes instead of sequence pattern linked to biochemical functions.
- 9. A methos as claimed in claim 1, wherein the unique outlier protein sequences non-homologous to the known anti-infective sequences specifically in the following pathogens

The state of the s

5

but not limited to, such as B.burgdorfei, C.jejuni, C.pneumoniae, C.trachomatis, H.influenzae, H.pylori, L.major, M.genetalium, M.pneumoniae, M.tuberculosis, N.meningitis, P.aeruginosa, P.falciparum, R.prowazekii, T.pallidum, V.cholerae.

- 10. A method as claimed in claim 1, wherein the unique outlier sequences obtained by the method of invention that can serve as potential anti-infective candidates as listed in Table 1 and list 1.
- 11. A method as claimed in claim 1, wherein The unique outlier hypothetical protein sequences from pathogenic genomes that can serve as anti-infective candidates listed in Table 2.
- 12. A method as claimed in claim 1, wherein the genes encoding the unique proteins useful as anti-infectives.
- 13. A method as claimed in claim 1, wherein the computer system comprises a central processing unit, executing DISTANCE program, clustering of the protein sequences based on different attributes using by Principle Component Analysis, all stored in a memory device accessed by CPU, a display on which the central processing unit displays the screens of the above mentioned programs in response to user inputs; and a user interface device.
- 14. A method as claimed in claim 1, wherein the unique outlier hypothetical protein sequences from pathogenic genomes that can be used for diagnostic purpose.

- 15. A method as claimed in claim 1, wherein the unique outlier hypothetical protein sequences from pathogenic genomes that can be used as vaccine candidates.
- 16. A method as claimed in claim 1, wherein The unique outlier hypothetical protein sequences from pathogenic genomes that can be used for therapeutic purposes.
- 17. Unique outlier protein sequences non-homologous to the known anti-infective sequences specifically in the following pathogens but not limited to such as as B.burgdorfei, C.jejuni, C.pneumoniae, C.trachomatis, H.influenzae, H.pylori, L.major, M.genetalium, M.pneumoniae, M.tuberculosis, N.meningitis, P.aeruginosa, P.falciparum, R.prowazekii, T.pallidum, V.cholerae.
- 18. Unique outlier protein sequences as claimed in claim 17, wherein the sequences obtained by the method of invention that can serve as potential anti-infective candidates as listed in Table 1 and List.
- 19. Unique outlier hypothetical protein sequences as claimed in claim 17, wherein the sequences from pathogenic genomes that can serve as anti-infective candidates listed in Table 2.